ISTH 2022 Congress
Venous Thromboembolism » Cancer Associated Thrombosis
Theme Navigation
- ISTH 2022 Congress
- Venous Thromboembolism
- Cancer Associated Thrombosis
- Venous Thromboembolism
-
Abstract Number: PB0933
A randomized clinical trial to evaluate the effect of rosuvastatin with enoxaparin on circulating tissue factor extracellular vesicles following ovarian cancer surgery
-
Abstract Number: PB0927
Abelacimab does not influence the effects of two commonly used antiplatelet agents in vitro
-
Abstract Number: PB0925
Abelacimab has no effect on platelet aggregation induced by TRAP-6 and collagen
-
Abstract Number: VPB0944
Anticoagulant associated bleeding risk assessment model for cancer associated thrombosis patients: A systematic review
-
Abstract Number: PB0914
Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer
-
Abstract Number: VPB0942
Association between RET and BRAF(V600) oncogenic status and risk of venous and pulmonary thromboembolism in patients with papillary thyroid cancer
-
Abstract Number: OC 16.5
Available Risk Scores Modestly Predict Hemorrhage in Patients with Cancer-Associated Thrombosis (CAT)
-
Abstract Number: VPB0940
Biomarkers of coagulopathy in patients with different types of acute leukemia
-
Abstract Number: PB0908
Bleeding versus thrombosis: Case series on dilemma of VTE management in cancer patients and role of radiotherapy
-
Abstract Number: OC 25.2
Cabozantinib Safety with Different Anticoagulants in Patients With Renal Cell Carcinoma (RCC)
-
Abstract Number: PB0930
Cancer associated thrombosis on bevacizumab: risk of recurrence and bleeding if bevacizumab is stopped or continued
-
Abstract Number: OC 32.5
CD146-positive tumors are associated with venous thromboembolism
-
Abstract Number: VPB0946
Clinical Impact of Thromboprophylaxis in Pancreatic Cancer Patients: data from ACT4CAT study
-
Abstract Number: PB0929
Comparison between full dose and reduced dose enoxaparin in the management of cancer-associated venous thromboembolism
-
Abstract Number: PB0911
Comparison of effectiveness and safety of direct oral anticoagulant versus low molecular weight heparin treatment for venous thromboembolism in patients with active cancer – the OSCAR UK Study
-
Abstract Number: PB0910
Comparison of standard vs low dose of direct oral anticoagulants for the secondary prophylaxis of venous thromboembolism in patients affected by hematologic malignancies
-
Abstract Number: PB0918
Comparison of the Khorana, PROTECHT and ONKOTEV risk assessment models to predict venous thromboembolism in patients with pancreatic cancer
-
Abstract Number: OC 16.4
COMPASS versus Khorana Risk Assessment Model for Predicting Venous Thromboembolic Events in Patients with Non-Small Cell Lung Cancer on Active Treatment with Chemotherapy and Immunotherapy.